Emerging from the UK, retatrutide, a new compound , is sparking considerable buzz within the scientific community regarding its promise for physique control . This dual GIP and GLP-1 receptor agonist seems to provide a significant advantage over established therapies, showing positive results in initial clinical assessments. Researchers suggest its